203 related articles for article (PubMed ID: 36503638)
1. Applying molecular measurable residual disease testing in acute myeloid leukaemia.
Krigstein M; Iland HJ; Wei AH
Pathology; 2023 Feb; 55(1):1-7. PubMed ID: 36503638
[TBL] [Abstract][Full Text] [Related]
2. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
4. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
5. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
[TBL] [Abstract][Full Text] [Related]
6. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
7. Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
Gronlund JK; Veigaard C; Juhl-Christensen C; Skou AS; Melsvik D; Ommen HB
Eur J Haematol; 2024 Apr; 112(4):601-610. PubMed ID: 38197567
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease testing in acute myeloid leukaemia.
Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
[TBL] [Abstract][Full Text] [Related]
9. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Ravandi F; Cloos J; Buccisano F; Dillon R; Döhner K; Freeman SD; Hourigan CS; Ossenkoppele GJ; Roboz GJ; Subklewe M; Thiede C; Arnhardt I; Valk PJM; Venditti A; Wei AH; Walter RB; Heuser M
Am J Hematol; 2023 Dec; 98(12):1847-1855. PubMed ID: 37671649
[TBL] [Abstract][Full Text] [Related]
10. Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A; Guzman ML
Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
[TBL] [Abstract][Full Text] [Related]
11. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
12. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A; Wakita S; Morita K; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Uoshima N; Kobayashi Y; Kawata E; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Kubota Y; Kimura S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Date K; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Ohashi K; Kanda Y; Yamaguchi H
Int J Hematol; 2022 Aug; 116(2):199-214. PubMed ID: 35377134
[TBL] [Abstract][Full Text] [Related]
13. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
15. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS; Ommen HB
Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
[TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
18. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
19. The present and future of measurable residual disease testing in acute myeloid leukemia.
Blachly JS; Walter RB; Hourigan CS
Haematologica; 2022 Dec; 107(12):2810-2822. PubMed ID: 36453518
[TBL] [Abstract][Full Text] [Related]
20. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
Dillon R; Potter N; Freeman S; Russell N
Br J Haematol; 2021 Apr; 193(2):231-244. PubMed ID: 33058194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]